6,916
Views
10
CrossRef citations to date
0
Altmetric
Original Research

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

, , , , , , , , , ORCID Icon, , , , ORCID Icon, , & show all
Article: e1450710 | Received 23 Oct 2017, Accepted 05 Mar 2018, Published online: 18 Apr 2018